A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...

Salvage surgery is feasible for NSCLC patients responding to targeted or immunotherapy, with a 36% pCR rate observed. The study included 30 patients, with 22 receiving immunotherapy and 8 receiving ...

Precision-targeted radiation is proving a match for surgery in early-stage lung cancer, offering patients similar long-term survival with less invasiveness, and potentially transforming how this ...

Breakthrough research presented at the 2026 Society of Thoracic Surgeons Annual Meeting shows that additional lymph node ...

A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new ...

Multidisciplinary evaluation, including thoracic surgical consultation, is crucial for oligometastatic NSCLC patients to optimize treatment strategies. Lung surgery for oligometastatic NSCLC shows ...

Significantly more facilities prescribe single-fraction stereotactic body radiation therapy than they did 20 years ago, but a minimal number of individuals with non-small cell lung cancer actually ...

Circular tumor DNA (ctDNA) positivity is associated with poorer survival and higher recurrence rates among patients with non–small cell lung cancer (NSCLC), but early detection may allow for timely ...

Please provide your email address to receive an email when new articles are posted on . Surgery and stereotactic ablative radiotherapy conferred comparable 10-year survival among patients with ...